Dong-A ST Co., Ltd. (KRX: 170900)

Market Cap	539.91B
Revenue (ttm)	700.31B
Net Income (ttm)	-24.22B
Shares Out	8.98M
EPS (ttm)	-9,747.34
PE Ratio	n/a
Forward PE	16.83
Dividend	686.27 (1.14%)
Ex-Dividend Date	n/a

Volume	24,891
Open	60,100
Previous Close	60,400
Day's Range	59,600 - 61,100
52-Week Range	54,200 - 88,000
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 14, 2025

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,687
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2023, Dong-A ST's revenue was 663.98 billion, an increase of 4.50% compared to the previous year's 635.39 billion. Earnings were 11.12 billion, a decrease of -17.93%.